| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G/A | 2019-02-14 | Capital International Investors | Juno Therapeutics, Inc. | - | 0.0% | EDGAR |
| SC 13G/A | 2018-03-09 | Arch Venture Fund VII LP | Juno Therapeutics, Inc. | - | - | EDGAR |
| SC 13G/A | 2018-03-09 | BAILLIE GIFFORD & CO | Juno Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13D/A | 2018-03-05 | CELGENE CORP /DE/ | Juno Therapeutics, Inc. | 99,227,867 | 85.4% | EDGAR |
| SC 13D/A | 2018-02-22 | CELGENE CORP /DE/ | Juno Therapeutics, Inc. | 11,109,160 | 9.7% | EDGAR |
| SC 13D/A | 2018-02-21 | CELGENE CORP /DE/ | Juno Therapeutics, Inc. | 11,109,160 | 9.7% | EDGAR |
| SC 13D/A | 2018-02-14 | CELGENE CORP /DE/ | Juno Therapeutics, Inc. | 11,109,160 | 9.7% | EDGAR |
| SC 13G | 2018-02-14 | Capital International Investors | Juno Therapeutics, Inc. | 7,680,487 | 6.7% | EDGAR |
| SC 13G/A | 2018-02-09 | VANGUARD GROUP INC | Juno Therapeutics, Inc. | 6,993,901 | 6.1% | EDGAR |
| SC 13D/A | 2018-02-07 | BRATTON DOUGLAS K | Juno Therapeutics, Inc. | 5,433,301 | 4.7% | EDGAR |
| SC 13D/A | 2018-02-02 | CELGENE CORP /DE/ | Juno Therapeutics, Inc. | 11,109,160 | 9.7% | EDGAR |
| SC 13G/A | 2018-02-02 | Arch Venture Fund VII LP | Juno Therapeutics, Inc. | 10,552,390 | 9.2% | EDGAR |
| SC 13D/A | 2018-01-22 | CELGENE CORP /DE/ | Juno Therapeutics, Inc. | 11,109,160 | 9.7% | EDGAR |
| SC 13G/A | 2018-01-10 | BAILLIE GIFFORD & CO | Juno Therapeutics, Inc. | 10,547,788 | 9.2% | EDGAR |
| SC 13D/A | 2017-11-08 | BRATTON DOUGLAS K | Juno Therapeutics, Inc. | 7,628,282 | 6.7% | EDGAR |
| SC 13D/A | 2017-09-26 | Celgene Switzerland LLC | Juno Therapeutics, Inc. | 11,109,160 | 9.7% | EDGAR |
| SC 13D/A | 2017-07-18 | BRATTON DOUGLAS K | Juno Therapeutics, Inc. | 9,348,799 | 8.8% | EDGAR |
| SC 13D/A | 2017-03-27 | Celgene Switzerland LLC | Juno Therapeutics, Inc. | 10,350,833 | 9.7% | EDGAR |
| SC 13G/A | 2017-02-14 | FMR LLC | Juno Therapeutics, Inc. | 1,918,667 | 1.8% | EDGAR |
| SC 13G/A | 2017-02-13 | Arch Venture Fund VII LP | Juno Therapeutics, Inc. | 10,552,390 | 10.0% | EDGAR |